Rheumatology Association of Nevada (RAN) 3rd Annual Meeting
Speakers
OVERVIEW
Rheumatology Association of Nevada (RAN) 3rd Annual Meeting is organized by WJ Weiser and Associates, Inc and will be held during Apr 27 - 28, 2018 at Hard Rock Hotel & Casino Lake Tahoe, Lake Tahoe, Nevada, United States of America. This CME Conference has been approved for a maximum of 5.75 AMA PRA Category 1 Credits.
Conference Objectives are :
• Describe the current therapeutic targets in the pathogenesis of RA.
• Explain the rationale for current strategies to inhibit cytokines in RA
• Recognize the effectiveness of novel monoclonal antibody and small molecule strategies in the treatment of RA.
• Explain the strategies in both methotrexate-naive and inadequate responders to withdraw biologics.
• Review the data supporting dose reduction of biologics.
• Explain the development of biosimilars and recent data supporting their approval and concerns for the clinician.
• Describe which characteristics best define an active (responsive) patient population in SLE clinical trials.
• Describe the challenges presented by use of active background therapy as the ‘placebo control’ and the importance of using definitions of “treatment failure”.
• Describe clinically meaningful outcomes that can assist interpretation of RCT data in SLE.
• Identify the common clinical characteristics shared by most auto-inflammatory conditions.
• Recognize key distinguishing patterns of lab studies obtained from patients with active auto-inflammatory conditions.
• Identify which key medications tend to be most effective for patients with auto-inflammatory conditions.
• Recognize when consulting a pediatric rheumatologist may be helpful in diagnosing and treating adults with auto-inflammatory conditions.
• Identify less typical presentations of GPA, MPA, and EGPA.
• List effective treatment options for patients with less typical ANCA-associated vasculitic syndromes.
Additional details will be posted as soon as they are available.
Conference Objectives are :
• Describe the current therapeutic targets in the pathogenesis of RA.
• Explain the rationale for current strategies to inhibit cytokines in RA
• Recognize the effectiveness of novel monoclonal antibody and small molecule strategies in the treatment of RA.
• Explain the strategies in both methotrexate-naive and inadequate responders to withdraw biologics.
• Review the data supporting dose reduction of biologics.
• Explain the development of biosimilars and recent data supporting their approval and concerns for the clinician.
• Describe which characteristics best define an active (responsive) patient population in SLE clinical trials.
• Describe the challenges presented by use of active background therapy as the ‘placebo control’ and the importance of using definitions of “treatment failure”.
• Describe clinically meaningful outcomes that can assist interpretation of RCT data in SLE.
• Identify the common clinical characteristics shared by most auto-inflammatory conditions.
• Recognize key distinguishing patterns of lab studies obtained from patients with active auto-inflammatory conditions.
• Identify which key medications tend to be most effective for patients with auto-inflammatory conditions.
• Recognize when consulting a pediatric rheumatologist may be helpful in diagnosing and treating adults with auto-inflammatory conditions.
• Identify less typical presentations of GPA, MPA, and EGPA.
• List effective treatment options for patients with less typical ANCA-associated vasculitic syndromes.
Additional details will be posted as soon as they are available.
KEY DATES
27 Apr, 2018
Event Start Date
28 Apr, 2018
Event End Date
SPECIALITIES
RheumatologySUGGESTED HOTELS
CONFERENCE VENUE
Hard Rock Hotel & Casino Lake TahoeRELATED CONFERENCES & LIVE WEBINARS
Quick Links